Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...
An MUSC research team reports in Cells that the complement system, part of the body’s natural immune defenses, is a key driver of inflammatory responses that contribute to fetal brain inflammation and ...
Cedars-Sinai investigators have identified a genetic variant that increases people's risk of developing perianal Crohn's disease, the most debilitating manifestation of Crohn's disease. Science X ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results